Maintenance infliximab (remicade) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the ACCENT I trial.

被引：19

作者：

Hanauer, SB

Lichtenstein, GR

Columbel, JF

Mayer, L

Schreiber, S

Rachmilewicz, D

Wolf, D

Malchow, H

Safdi, M

Feagan, B

Olson, A

Rutgeerts, P

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Hosp Univ Penn, Philadelphia, PA 19104 USA

[3] Hosp Claude Huriez, Lille, France

[4] Mt Sinai Med Ctr, New York, NY 10029 USA

[5] Univ Kiel, Kiel, Germany

[6] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[7] Atlanta Gastroenterol Assoc, Atlanta, GA USA

[8] Clin Leverkusen, Leverkusen, Germany

[9] Greater Cincinnati Gastroenterol Assoc Inc, Atlanta, GA USA

[10] Univ Western Ontario, London, ON, Canada

[11] Centocor Inc, Malvern, PA 19355 USA

[12] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

来源：

关键词：

D O I：

10.1016/S0016-5085(08)80101-1

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：A21 / A21

页数：1